Absci

Absci FCF Growth

The Year-over-Year Free Cash Flow Growth of Absci (ABSI) as of Oct 17, 2026 is -29.15 %. In the previous year, Year-over-Year Free Cash Flow Growth was -11.16 % — a change of 161.22% (lower).

FCF Growth

-29.15 %

YoY

161.22%

Last updated:

Year-over-Year Free Cash Flow Growth of Absci is 2025 -29.15 % . Year-over-Year Free Cash Flow Growth of Absci was 2024 -11.16 % . It decreases by 161.22% lower compared to the previous year.

The Absci FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2020
-84.45 USD
Jan 1, 2021
-650.10 USD
Jan 1, 2022
1.15 USD
Jan 1, 2023
32.83 USD
Jan 1, 2024
-11.16 USD
Jan 1, 2025
-29.15 USD
The Absci FCF Growth history
YEARFCF GrowthYoY
-29.15 %+161.22%
-11.16 %-133.99%
32.83 %+2,763.78%
1.15 %-100.18%
-650.10 %+669.84%
-84.45 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Absci Stock analysis

What does Absci do? Absci Corp, trading under the ticker ABSI with ISIN US00091E1091, is a biotechnology company headquartered in Vancouver, Washington, operating within the Health Care sector. The company went public via an IPO on July 22, 2021. Absci employs 140 people. It leverages artificial intelligence and synthetic biology to explore and expand the therapeutic potential of proteins. The company utilizes a platform combining AI with scalable wet lab technologies to develop biologics for patients. Absci's approach involves identifying novel drug targets, discovering biotherapeutic candidates, and generating cell lines for manufacturing within a single integrated process. The firm applies generative AI to design drug candidates optimized for target affinity, safety, manufacturability, and other characteristics. Absci's technology includes SoluPro, a multiplex synthetic biology method that addresses limitations of high-throughput automation labs. The company supports its AI-driven designs with high-throughput functional validation capabilities in its wet lab. Absci's website is www.absci.com, providing information about its services and technology. The company focuses on creating biologic drug candidates for partners, using data generated from its processes to refine and improve its platform. Absci is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Absci stock

Year-over-Year Free Cash Flow Growth of Absci is -29.15 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth Absci since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's Absci historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Absci

All Key Metrics — Absci